Skip to main content

Table 1 Characteristics of patients with rheumatoid arthritis in the two treatment groups

From: Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept

 

Treatment

Patients

Infliximab

Etanercept

No.

32

17

Age (years)a

56.7 (23.5–80.9)

55.3 (23.2–70.4)

Female/male

25/7

10/7

Duration of disease (years)a

12.9 (3.0–55.5)

13.7 (2.5–41.0)

Serum CRP at baseline (mg/l)a

20 (1–84)

36 (1–85)

Serum COMP at baseline (u/l)a

11.3 (5.5–19.2)

12.2 (8.1–29.7)

DAS28 at baselinea

5.3 (2.4–8.1)

5.9 (3.7–7.5)

HAQ at baselinea

1.4 (0.4–2.8)

1.6 (0.3–2.8)

Monotherapy/combination therapy 5/27

 

3/14

Prednisolone/no prednisolone

20/12

11/6

ACR20 response at 3 months

16 (50%)

11 (65%)

  1. There were no significant differences between the groups. aMedian (range). ACR20 = 20% improvement according to the American College of Rheumatology criteria; CRP = C-reactive protein; COMP = cartilage oligomeric matrix protein; DAS = disease activity score; HAQ = health assessment questionnaire.